Key terms
About INMB
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest INMB news
Apr 12
1:35am ET
Inmune Bio’s INB03 Shows Promise as Pan-Immune Checkpoint Inhibitor: A Buy Rating from Analyst Joel Beatty
Apr 08
8:19am ET
INmune Bio presents data on INB03’s role as immune check point
Apr 02
4:10pm ET
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Inmune Bio (INMB)
Mar 06
1:56pm ET
Buy Rating Affirmed for Inmune Bio Amid Promising Alzheimer’s Treatment Developments
Mar 05
8:11am ET
INmune Bio reports ‘significant’ EEG improvement in patients treated with Xpro
Feb 02
5:25am ET
BTIG Remains a Buy on Inmune Bio (INMB)
Feb 01
12:37am ET
Buy Rating Affirmed: Inmune Bio’s XPro Progresses with FDA’s Green Light and Unique Therapeutic Approach
Jan 31
12:35pm ET
Inmune Bio’s Buy Rating Affirmed Amid Positive Alzheimer’s Program Developments
Jan 30
8:05am ET
INmune Bio announces FDA removal of clinical hold for Alzheimer disease program
Jan 18
11:32am ET
Biotech Alert: Searches spiking for these stocks today
No recent press releases are available for INMB
INMB Financials
Key terms
Ad Feedback
INMB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
INMB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
